Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) [Phase 3]
Phase 3 trial evaluating oral ixazomib as maintenance therapy after initial therapy in newly diagnosed multiple myeloma patients not treated…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 dose-escalation trial evaluating WT1-specific donor-derived T cells after T-cell–depleted allogeneic stem cell transplantation in re…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: REST - Replacing Steroids in the Transplant Ineligble [Phase 2]
A Phase 2 trial update on REST (Replacing Steroids in the Transplant Ineligible) for multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) [Phase 2]
Phase 2 NCI MATCH subprotocol V is evaluating sunitinib for cancers with cKIT genetic alterations, including advanced and refractory lymphom…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications [Phase 1, Phase 2]
A Phase 1/2 clinical trial of KPT-8602 (eltanexor) in participants with relapsed/refractory cancer indications completed, evaluating safety,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma [Phase 2]
Phase 2 trial update on Teclistamab-Daratumumab and Talquetamab-Daratumumab combinations in newly diagnosed high-risk multiple myeloma; the …
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating a conditioning regimen with panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell tra…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma [Phase 3]
This Phase 3 clinical trial compares belantamab mafodotin plus pomalidomide and dexamethasone against bortezomib plus pomalidomide and dexam…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial evaluates PF-06863135 as a single agent and in combination with immunomodulatory agents in relapsed/refractory multiple myel…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) [NA]
The PHANTASTIC trial evaluating plerixafor-assisted, chemotherapy-free autologous stem cell transplantation for cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: NXC-201 (formerly HBI0101) Multiple Myeloma [Phase 1]
A Phase 1 trial of NXC-201 (formerly HBI0101) for multiple myeloma is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: Ixazomib Rollover Study [Phase 2]
A Phase 2 Ixazomib rollover study has completed, with results posted on 2025-03-12. The study encompassed multiple myeloma, lymphoma, and am…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma [Phase 1, Phase 2]
Results from a Phase 1/2 trial of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone for relapsed and refra…
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM [Phase 1, Phase 2]
Results from a sub-study of belantamab mafodotin as monotherapy and in combination with dostarlimab in relapsed/refractory multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma [Phase 2]
Phase 2 study evaluating daratumumab in combination with pomalidomide, dexamethasone, and all-trans retinoic acid in multiple myeloma was te…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
An observational study in multiple myeloma reports presentation, treatment patterns, and outcomes; the study has been terminated and results…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating all-trans retinoic acid with a KPD regimen for relapsed or refractory multiple myeloma. The study is curre…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic [Phase 2]
Phase 2 trial in relapsed and refractory multiple myeloma evaluating IPD characterized by adverse prognostic genomic abnormalities; the stud…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 study assessing safety and pharmacokinetics of XMAB24306 in combination with Daratumumab for relapsed/refractory multiple myeloma; t…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Myeloma-Developing Regimens Using Genomics (MyDRUG) [Phase 1, Phase 2]
Phase 1/2 trial named MyDRUG investigates genomics-guided regimens for relapsed or refractory multiple myeloma. The study has completed enro…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT [Phase 1, Phase 2]
A Phase 1/Phase 2 trial investigating elotuzumab with anti-LAG-3 and anti-TIGIT antibodies for multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients [Phase 2]
Phase 2 study of denosumab in high-risk smoldering multiple myeloma and SLiM-CRAB positive early multiple myeloma patients has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Respiatory Viral Infections in Patients With Multiple Myeloma
The study investigating respiratory viral infections in patients with multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation [Phase 1]
Phase 1 study evaluating daratumumab in combination with lenalidomide and dexamethasone in Japanese patients with previously untreated multi…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
This completed real-world analysis examines patterns of belantamab mafodotin use in patients with relapsed/refractory multiple myeloma and d…